InvestorsHub Logo
Followers 74
Posts 10290
Boards Moderated 1
Alias Born 11/22/2004

Re: None

Friday, 12/13/2019 8:16:18 AM

Friday, December 13, 2019 8:16:18 AM

Post# of 647879
CORV pipeline at .39. "Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil."

Rayank

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.